剂量密集型短期方案治疗MYC易位侵袭性淋巴瘤的安全性与疗效
回顾性分析5家意大利中心68例MYC重排侵袭性B细胞淋巴瘤(伯基特淋巴瘤46例,高级别B细胞淋巴瘤22例)患者,接受CARMEN方案(36天诱导+大剂量阿糖胞苷巩固)治疗。全疗程完全缓解率在高级别B细胞淋巴瘤为73%(95%CI 55%-91%),伯基特淋巴瘤为78%(95%CI 66%-90%);中位随访65个月,5年无进展生存率分别为63%和72%。作者认为CARMEN在HIV阴性和阳性患者中安全且有效,但需进一步研究。
要点
- 68例MYC重排侵袭性淋巴瘤(伯基特淋巴瘤46例,高级别B细胞淋巴瘤22例)接受CARMEN方案,61例(90%)完成诱导,59例(87%)完成巩固。
- 全疗程完全缓解率:高级别B细胞淋巴瘤73%(95%CI 55%-91%),伯基特淋巴瘤78%(95%CI 66%-90%)。
- 5年无进展生存率:高级别B细胞淋巴瘤63%(95%CI 58%-68%),伯基特淋巴瘤72%(95%CI 71%-73%);5年总生存率分别为63%(95%CI 58%-68%)和76%(95%CI 75%-77%)。
核心结论
- 这项回顾性研究显示,CARMEN方案在HIV阴性和阳性的MYC重排淋巴瘤患者中安全且有效。
- 作者认为,单次多柔比星和环磷酰胺所取得的令人鼓舞的生存数据值得在高级别B细胞淋巴瘤和其他侵袭性淋巴瘤中进一步研究。
研究设计与样本
- 回顾性研究,在5家意大利中心纳入68例经荧光原位杂交检测存在MYC重排的侵袭性B细胞淋巴瘤患者,其中伯基特淋巴瘤46例,高级别B细胞淋巴瘤(单打击、双打击或三打击)22例。
- 46例(68%)患者HIV阳性。
- CARMEN方案包括36天诱导治疗(环磷酰胺、长春新碱、利妥昔单抗、甲氨蝶呤、依托泊苷和多柔比星每周序贯单次给药,联合鞘内化疗),随后进行以大剂量阿糖胞苷为基础的巩固治疗。
- 诱导后未达到完全缓解的患者在巩固治疗后接受BEAM(卡莫司汀、依托泊苷、阿糖胞苷、美法仑)预处理的自体造血干细胞移植。
主要发现
- 61例(90%)患者完成诱导治疗,59例(87%)完成巩固治疗;17例患者接受了自体造血干细胞移植。
- 4级血液学毒性常见,但未导致治疗中止;11例(16%)患者记录到4级非血液学毒性,其中6例(9%)为4级感染。
- 6例(9%)患者死于毒性(脓毒症4例、COVID-19、急性呼吸窘迫综合征)。
- 全疗程完全缓解率:高级别B细胞淋巴瘤为73%(95%CI 55%-91%),伯基特淋巴瘤为78%(95%CI 66%-90%)。
- 中位随访65个月(四分位距40-109个月),48例患者保持无事件生存;5年无进展生存率在高级别B细胞淋巴瘤为63%(95%CI 58%-68%),在伯基特淋巴瘤为72%(95%CI 71%-73%);5年总生存率分别为63%(95%CI 58%-68%)和76%(95%CI 75%-77%)。
关键数值与推荐
- 全疗程完全缓解率:高级别B细胞淋巴瘤73%(95%CI 55%-91%),伯基特淋巴瘤78%(95%CI 66%-90%)。
- 5年无进展生存率:高级别B细胞淋巴瘤63%(95%CI 58%-68%),伯基特淋巴瘤72%(95%CI 71%-73%)。
- 5年总生存率:高级别B细胞淋巴瘤63%(95%CI 58%-68%),伯基特淋巴瘤76%(95%CI 75%-77%)。
- 4级非血液学毒性11例(16%),4级感染6例(9%),毒性相关死亡6例(9%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文在结论中提出,单次多柔比星和环磷酰胺所取得的生存数据值得在高级别B细胞淋巴瘤和其他侵袭性淋巴瘤中进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with aggressive B-cell lymphoma and MYC rearrangement at fluorescence in situ hybridization exhibit poor outcome after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). In the last decade, 68 patients with Burkitt lymphoma ([BL] n = 46) or high-grade B-cell lymphoma ([HGBCL] single, double, or triple hit; n = 22) were treated with a dose-dense, short-term therapy termed "CARMEN regimen" at 5 Italian centers. Forty-six (68%) patients were HIV+. CARMEN included a 36-day induction with sequential, single weekly doses of cyclophosphamide, vincristine, rituximab, methotrexate, etoposide, and doxorubicin plus intrathecal chemotherapy, followed by high-dose-cytarabine-based consolidation. Patients who did not achieve complete remission (CR) after induction received BEAM (carmustina, etoposide, cytarabine, melfalan)-conditioned autologous stem cell transplantation (ASCT) after consolidation. Sixty-one (90%) patients completed induction, and 59 (87%) completed consolidation. Seventeen patients received ASCT. Grade 4 hematological toxicity was common but did not cause treatment discontinuation; grade 4 nonhematological toxicity was recorded in 11 (16%) patients, with grade 4 infections in 6 (9%). Six (9%) patients died of toxicity (sepsis in 4, COVID-19, acute respiratory distress syndrome). CR rate after the whole treatment was 73% (95% confidence interval [CI], 55% to 91%) for patients with HGBCL and 78% (95% CI, 66% to 90%) for patients with BL. At a median follow-up of 65 (interquartile range, 40-109) months, 48 patients remain event free, with a 5-year progression-free survival of 63% (95% CI, 58% to 68%) for HGBCL and 72% (95% CI, 71% to 73%) for BL, with a 5-year overall survival (OS) of 63% (95% CI, 58% to 68%) and 76% (95% CI, 75% to 77%), respectively. HIV seropositivity did not have a detrimental effect on outcome. This retrospective study shows that CARMEN is a safe and active regimen both in HIV-negative and -positive patients with MYC-rearranged lymphomas. Encouraging survival figures, attained with a single dose of doxorubicin and cyclophosphamide, deserve further investigation in HGBCL and other aggressive lymphomas.
引用
- Ferreri AJM, Angelillo P, Erbella F, et al. Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma. Blood Adv. 2022. PMID: 35580327. doi:10.1182/bloodadvances.2022007475
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。